Skyrizi vs Ilumya. What’s the difference?

Q: Skyrizi vs Ilumya. What’s the difference?

There are a number of differences between Skyrizi and Ilumya: Ilumya was FDA approved in 2018 and Skyrizi was FDA approved in 2019. Ilyumya is a brand name for tildrakizumab and Skyrizi is a brand name for risankizumab The dose of Skyrizi is 150mg, but because each injection only contains 75mg, two injections must be given per dose. The dose of Ilumya is 100mg, and each injection contains 100mg therefore only one injection needs to be given each time Ilumya needs to be administered by a healthcare professional; however, patients prescribed Skyrizi can be taught how to self-administer it at home Skyrizi is also approved to treat adults with active psoriatic arthritis (PsA), Crohn's disease, and ulcerative colitis.

Medically reviewed by Carmen Pope, BPharm. Last updated on July 26, 2024.

Official Answer by Drugs.com

Both Skyrizi and Ilumya are IL-23 monoclonal antibodies that may be given for the treatment of moderate to severe plaque psoriasis. There are several differences between them:

Ilumya was FDA approved in 2018 and Skyrizi was FDA approved in 2019
Ilyumya is a brand name for tildrakizumab and Skyrizi is a brand name for risankizumab
The dose of Skyrizi is 150mg, but because each injection only contains 75mg, two injections must be given per dose. The dose of Ilumya is 100mg, and each injection contains 100mg therefore only one injection needs to be given each time
Ilumya needs to be administered by a health care professional; however, patients prescribed Skyrizi can be taught how to self-administer it at home
Skyrizi is also approved to treat adults with active psoriatic arthritis (PsA), Crohn's disease, and ulcerative colitis.

Comparative trials comparing Skyrizi to Ilumya are lacking; however, a trial that compared Skyrizi to Stelara showed that it has a fast onset of action with 44% of participants achieving PASI 90 by week four compared with only 19% of those administered Stelara.

There are several similarities between Skyrizi and Ilumya:

Both are approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Both Skyrizi and Ilumya are dosed every 12 weeks after an initial loading dose period
Either may be given as monotherapy or in addition to other therapies
Side effects are similar.

References

Skyrizi Injection (risankizumab-rzaa) 06/2024. AbbVie Inc. https://www.rxabbvie.com/pdf/skyrizi_pi.pdf
Ilumya (tildrakizumab-asmn) 04/2024. Sun Pharmaceutical Industries, Inc. https://www.drugs.com/pro/ilumya-injection.html

What are Monoclonal Antibodies and how do they work?

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis.

What are IL-23 Inhibitors and how do they work?

IL-23 inhibitors represent a class of biologic medications that target interleukin-23 (IL-23), a key inflammatory cytokine that plays a central role in driving immune system dysfunction.

What's the dosing schedule for Skyrizi?

After your initial starter doses, you'll receive Skyrizi as subcutaneous (under the skin) maintenance dose every 12 weeks (4 times per year) to treat either plaque psoriasis or psoriatic arthritis, or every 8 weeks (6 times per year) to treat either Crohn's disease or ulcerative colitis. You can self-administer these injections at home after proper training from your healthcare provider. Continue reading

Skyrizi vs Ilumya. What’s the difference?

Read next

What are Monoclonal Antibodies and how do they work?

What are IL-23 Inhibitors and how do they work?

What's the dosing schedule for Skyrizi?

See also:

Ozempic

Trulicity

Otezla

Lantus

Tresiba

Basaglar

Levemir

Novolog

Victoza

Toujeo SoloStar

Related medical questions

Drug information

Related support groups